Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Stomach Neoplasms 43Carcinoma, Hepatocellular 41Carcinoma, Non-Small-Cell Lung 17Colorectal Neoplasms 14Breast Neoplasms 14Small Cell Lung Carcinoma 12Sarcoma 11Ovarian Neoplasms 11Nasopharyngeal Carcinoma 11Triple Negative Breast Neoplasms 10Lung Neoplasms 10Cholangiocarcinoma 10Esophageal Squamous Cell Carcinoma 9Esophageal Neoplasms 9Osteosarcoma 8Biliary Tract Neoplasms 8Advanced Gastric Cancer 8Neoplasms 6Head and Neck Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Recurrence 5Pancreatic Neoplasms 5Neoplasm Metastasis 5Liver Neoplasms 5Glioma 5Drug-Related Side Effects and Adverse Reactions 4Thyroid Neoplasms 3Melanoma 3Gastrointestinal Neoplasms 3

Interventions

poly(I).poly(c12,U) 1pembrolizumab 1mirabegron 1liposomal doxorubicin 1disitamab vedotin 1apatinib 1anlotinib 1Tocotrienols 1Platinum Compounds 1Paclitaxel 1Lenalidomide 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Cisplatin 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Cancer Recurrent × apatinib × Clear all
NCT06102707 2023-10-26

The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients

Qilu Hospital of Shandong University

Phase NA Not yet recruiting
50 enrolled
Gynecologic

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡